• DOI:10.1186/s12913-021-06103-1
• Corpus ID: 231706340

Prescribers’ perspectives on including reason for use information on prescriptions and medication labels: a qualitative thematic analysis

@article{Whaley2021PrescribersPO,
  title={Prescribers’ perspectives on including reason for use information on prescriptions and medication labels: a qualitative thematic analysis},
  author={Colin RJ Whaley and Ashley Bancsi and Joanne Man-Wai Ho and Catherine M. Burns and Kelly Anne Grindrod},
  journal={BMC Health Services Research},
  year={2021},
  volume={21}
}

• C. Whaley, Ashley Bancsi, +2 authors K. Grindrod
• Published 26 January 2021
• Medicine, Political Science
• BMC Health Services Research

Background The indication for prescribing a particular medication, or its reason for use (RFU) is a crucial piece of information for all those involved in the circle of care. Research has shown that sharing RFU information with physicians, pharmacists and patients improves patient safety and patient adherence, however RFU is rarely added on prescriptions by prescribers or on medication labels for patients to reference. Methods Qualitative interviews were conducted with 20 prescribers in Southern Ontario, Canada, to learn prescribers’ current attitudes on the addition of RFU on prescriptions and medication labels. A trained interviewer used a semi-structured interview guide for each interview. The interviews explored how the sharing of RFU information would impact prescribers’ workflows and practices. Interviews were recorded, transcribed and thematically coded. Results The analysis yielded four main themes: Current Practice, Future Practice, Changing Culture, and Collaboration. Most of the prescribers interviewed do not currently add RFU to prescriptions. Prescribers were open to sharing RFU with colleagues via a regional database but wanted the ability to provide context for the prescribed medication within the system. Many prescribers were wary of the impact of adding RFU on their workflow but felt it could save time by avoiding clarifying questions from pharmacists. Increased interprofessional collaboration, increased patient understanding of prescribed medications, avoiding guesswork when determining indications and decreased misinterpretation regarding RFU were cited by most prescribers as benefits to including RFU information. Conclusions Prescribers were generally open to sharing RFU and clearly identified the benefits to pharmacists and patients if added. Critically, they also identified benefits to their own practices. These results can be used to guide the implementation of future initiatives to promote the sharing of RFU in healthcare teams.